Potassium chloride

Generic Name: Potassium chloride

Brand Names: Bi-peglyte, Bss, Bss Ophthalmic Solution, Cardioplegic, Citrasate, Colyte, Dextrose and Electrolyte No. 75, Diphen, Eye Stream, Gavilyte-C, Gavilyte-G, Gavilyte-H and Bisacodyl, Gavilyte-N, Glycerolyte 57, Golytely, H.E.L.P.bicel, Hemosate Ultra, Ionosol-MB, Isolyte P, Isolyte S, Isolyte S pH 7.4, Isoplate, K 45, K-tab, Klor-con, Lactated Ringers, Moviprep, Naturalyte, Normosol-R, Nulytely, Nxstage Pureflow, Olimel, Peglyte, Periolimel, Phoxillum, Physiolyte, Physiosol, Plasma-lyte, Plasma-lyte 148, Plasma-lyte 148 In 5 % Dextrose, Plasma-lyte R, Plasmalyte A, Plegisol, Plenvu, Pokonza, Prismasol, Procalamine 3, Ringers, Selectbag One, Suflave, Tis-U-sol

Drug Type: Small Molecule

Chemical Formula: ClK

CAS Number: 7447-40-7

Unique Ingredient Identifier: 660YQ98I10

Background: A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives.

The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium per dosage unit, except for controlled-release dosage forms and those products formulated for preparation of solution prior to ingestion.

Indication: For use as an electrolyte replenisher and in the treatment of hypokalemia.

Associated Conditions: Dehydration, Dry Mouth, Hypokalemia, Hypotonic Dehydration, Hypovolaemia, Isotonic Dehydration, Markedly Reduced Food Intake, Metabolic Acidosis, Hypodermoclysis, Mild Metabolic acidosis, Mild, moderate Metabolic Acidosis, Ocular edema

Associated Therapies: Acid- Base Balance, Bowel preparation therapy, Electrolyte replacement, Fluid replacement therapy, Haemofiltration, Hemodialysis Treatment, Parenteral Nutrition, Parenteral rehydration therapy, Plasma Volume Replacement, Urine alkalinization therapy, Fluid and electrolyte maintenance therapy

Clinical Trials

Targeting Pulsatile Load to Increase Exercise Capacity and Quality of Life After Aortic Valve Replacement for Severe Aortic Stenosis (PULSE AS)

Phase 2

Completed

Conditions: Aortic Valve Stenosis

Interventions: Drug: Potassium Nitrate
Drug: Potassium Chloride

First Posted Date: 2018-03-29

Last Posted Date: 2020-06-17

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 5

Registration Number: NCT03483051

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

A Pharmacokinetic Study of PLENVU® in Healthy Subjects

Phase 1

Completed

Conditions: Pharmacokinetic

Interventions: Drug: PLENVU powder for oral solution

First Posted Date: 2018-02-19

Last Posted Date: 2023-11-29

Lead Sponsor: Norgine

Target Recruit Count: 19

Registration Number: NCT03437265

Locations: 🇬🇧
Quotient Sciences (Quotient),, Ruddington, Nottingham, United Kingdom

Microbiota Transfer Therapy for Adults With Autism Spectrum Disorder (ASD) Who Have Gastrointestinal Disorders

Phase 2

Active, not recruiting

Conditions: Gastrointestinal Disorder
Autism Spectrum Disorder

Interventions: Drug: Vancomycin
Drug: MoviPrep
Biological: Full Spectrum Microbiota

First Posted Date: 2018-01-24

Last Posted Date: 2023-01-09

Lead Sponsor: Arizona State University

Target Recruit Count: 55

Registration Number: NCT03408886

Locations: 🇺🇸
Arizona State University, Tempe, Arizona, United States

Safety and Efficacy Study of an Edible Colonoscopy Preparation

Phase 2

Completed

Conditions: Colon Prep for Colonoscopy

Interventions: Drug: MoviPrep®
Drug: ECP Colon Prep Kit

First Posted Date: 2017-11-06

Last Posted Date: 2018-03-19

Lead Sponsor: Sebela Pharmaceuticals Development LLC

Target Recruit Count: 60

Registration Number: NCT03332485

Locations: 🇺🇸
Sebela Site 006, Indianapolis, Indiana, United States
🇺🇸
Sebela Site 001, Mentor, Ohio, United States
🇺🇸
Sebela Site 003, Annapolis, Maryland, United States

and more 5 locations